Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Plus Pembrolizumab With or Without Lenalidomide in Relapsed Follicular Lymphoma and DLBCL
NCT02446457Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2015
- Primary completion
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2015; status: active, not recruiting.
02
Drugs
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02446457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02446457.